A Republican-led House panel has advanced a 2024 budget bill that includes riders to revoke key Food and Drug Administration (FDA) approvals regarding where patients are allowed to access abortion drug mifepristone, in a quiet move aimed at limiting abortion access nationwide.
The legislation passed the House Agriculture, Rural Development, Food and Drug Administration Appropriations Subcommittee by voice vote on Thursday. It would revoke the FDA decision to nix the requirement for mifepristone to be obtained in person and allow it to be prescribed via telehealth and received by mail, which was first announced by the agency in 2021.
